Mundipharma International Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mundipharma International Limited
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.
In a close but negative panel vote on the company’s acute respiratory distress syndrome treatment VERU-111 (sabizabulin), majority of US FDA advisory committee says more study should come ahead of an emergency use authorization, not as an authorization condition.
Agency poised to authorize Veru’s NME for COVID acute respiratory distress despite potential efficacy concerns and an unusually small safety database even by EUA standards. FDA assessment highlights continued burden of COVID despite political rhetoric downplaying current impact.
- OTC, Consumer
- Controlled Release
- Other Names / Subsidiaries
- Cinfa Biotech GmbH
- Mundipharma Biologics S.L.
- Mundipharma EDO GmbH
- Napp Pharmaceuticals Ltd.
- Tolmar Australia Pty. Ltd.